Evidence map›Paper›PMID 17372693›Full record

ReviewPharmaceutical research2007

Encapsulation of nucleic acids and opportunities for cancer treatment.

Lisa Brannon-Peppas, Bilal Ghosn, Krishnendu Roy, Kenneth Cornetta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lisa Brannon-PeppasDepartment of Biomedical Engineering and College of Pharmacy, The University of Texas at Austin, 1 University Station, Mailcode C0300, Austin, TX 78712, USA. peppas@mail.utexas.edu
Bilal Ghosn
Krishnendu Roy
Kenneth Cornetta
The University of Texas at Austin · USIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of nucleic acid drugs for the treatment of various cancers has shown great promise in recent years. However, efficient delivery of these drugs to target cells remains a significant challenge towards the successful development of such therapies. This review provides a comprehensive overview of encapsulation technologies being developed for the delivery of nucleic acid-based anti-cancer agents. Both micro and nanoparticles systems are discussed along with their use in delivering plasmid DNA as well as oligonucleotides. The majority of the systems discussed have used DNA immunotherapy as the potential mode of anticancer therapy, which requires targeting to antigen presenting cells. Other applications, including those with oligonucleotides, focus on targeting tumor cells directly. The results obtained so far show the excellent promise of encapsulation as an efficient means of delivering therapeutic nucleic acids.

Indexed as

Gene Transfer TechniquesAnimalsAntigen-Presenting CellsAntineoplastic AgentsDNAGenetic TherapyHumansImmunotherapyNanotechnologyNeoplasmsNucleic AcidsOligonucleotides, AntisenseParticle SizePlasmidsPolymersAntineoplastic AgentsDNANucleic AcidsOligonucleotides, AntisensePolymers

Identifiers

PMID17372693
OpenAlexW1997393089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.